Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP
Go back to Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP| BANCO SANTANDER S.A. (NYSE: SAN) | Delayed: 13.50 -0.1 (0.74%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.60 | 52 Week High | $5.58 | |||
| Open | $13.50 | 52 Week Low | $3.60 | |||
| Day High | $13.50 | P/E | N/A | |||
| Day Low | $13.50 | EPS | $0.00 | |||
| Volume | 142,419 | |||||
| SANOFI (NASDAQ: SNY) | Delayed: 41.60 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $41.60 | 52 Week High | $44.76 | |||
| Open | $41.60 | 52 Week Low | $36.81 | |||
| Day High | $41.60 | P/E | N/A | |||
| Day Low | $41.60 | EPS | $0.00 | |||
| Volume | 39,565 | |||||
